Aktis Oncology
About Aktis Oncology
Aktis Oncology is a biotechnology company focused on transforming cancer care with novel platform technologies that enable the design and development of precision radiopharmaceuticals. These targeted therapies harness the potent anticancer effects of alpha-emitting particles. The company is pursuing a broad set of targets in commonly occurring cancers to create radiopharmaceuticals that could provide treatment options where currently limited therapies exist.
Recent News
TerraPower Commits $450M to Build Radioisotope Production Plant
Insilico’s Big Gain After Hong Kong Listing: Finance Report
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Brisk Demand for Follow-Ons Could Augur IPO Appetite: Public Equity Report
Aktis Lands Biotech's First IPO of 2026, Raising $318M for Radiopharmaceuticals
Regeneron Enters Radiopharma Ring with up to $4.3B Telix Alliance
Eikon Prices Its IPO, Seeking to Raise $318m
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
The Biggest Biotech Funding Rounds in January 2026
Three More Biotechs Price Their Nasdaq IPOs
